Editorials in 2019

Filter By:

Article Type
Year
  • 150 years after its founding, Nature has not only published some of biotech’s seminal papers, but also profoundly influenced the sector’s impact on society.

    Editorial
  • China is set to challenge the pre-eminence of the US drug market. If it can address gaps in its R&D ecosystem and clinical infrastructure, it may even become a home for biotech innovators.

    Editorial
  • To capitalize on progress in neuromodulation, funders and clinicians should promote not only translational research, but also data sharing.

    Editorial
  • Heavy-handed targeting of ethnic Chinese researchers, students and investors by US funding, intelligence and immigration agencies poses a threat to the American life-sciences sector.

    Editorial
  • Sky-high-priced gene therapies face slow uptake and market failure unless healthcare payers and drug makers can find common ground in ‘pay-for-performance’ reimbursement.

    Editorial
  • Nature Biotechnology’s peer review trial with Code Ocean highlights the importance of ‘containers’ in enhancing software usability, reproducibility and code-writing in academia.

    Editorial
  • The outgoing FDA commissioner’s comments on the slow integration of data from mobile platforms into clinical research highlight the challenges facing real-world applications of wearables.

    Editorial
  • Biomedical research and healthcare has traditionally centered on disease rather than health. Several projects gathering data on healthy people promise to change that.

    Editorial
  • The acquisition of Celgene is bad news for young biotech companies with innovative products and platforms to sell.

    Editorial
  • The CRISPR baby furor is a clarion call to scientific and government bodies to define acceptable candidate diseases and minimal technical requirements for germline gene editing and to redouble outreach to, and oversight of, IVF clinics.

    Editorial